Immunologic Factors: all 3,292 studies that test it
Page 3 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- Bortezomib, Pomalidomide, Dexamethasone for Systemic AL AmyloidosisRecruitingNCT06342466Phase 2
- Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)RecruitingNCT06341205Phase 3
- Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaRecruitingNCT06337318Phase 3
- Ma-Spore ALL 2020 StudyRecruitingNCT06336395Phase 2
- Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT06263491Phase 2
- Rituximab for Serious Aplastic Anemia With Platelet Transfusion RefractorinessRecruitingNCT06254560Phase 2
- the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous NephropathyRecruitingNCT06245707Not applicable
- Optimizing Reversal of HIV Latency With Combination TherapyNot yet recruitingNCT06240520Phase 1/2
- CC-99282 + Rituximab Early Post CART for Non-Hodgkin's LymphomaRecruitingNCT06209619Phase 1
- Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple MyelomaRecruitingNCT06209606Early Phase 1
- BV-AVD-R Treatment Children Hodgkin's LymphomaEnrolling by invitationNCT06201507Phase 2
- RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT LymphomaRecruitingNCT06190301Not applicable
- Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUSRecruitingNCT06189833Phase 2
- FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)RecruitingNCT06187441Phase 3
- IVIG in Painful Sensory NeuropathyNot yet recruitingNCT06183008Phase 4
- MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive ImpairmentNot yet recruitingNCT06177028Phase 2
- Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL PatientsRecruitingNCT06176729Phase 2
- Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell ImpairmentRecruitingNCT06159283Phase 2
- IVIG Boya: Safety, Efficacy, and PharmacokineticsNot yet recruitingNCT06150833Phase 3
- A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaRecruitingNCT06149286Phase 3
- A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell LymphomaRecruitingNCT06136351Phase 2
- Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIGNot yet recruitingNCT06089122Phase 3
- Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)RecruitingNCT06087653Phase 1/2
- A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCLRecruitingNCT06086197Phase 2
- Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated DonorRecruitingNCT06083129Phase 3
- PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUMNot yet recruitingNCT06066255Phase 2
- RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT LymphomaNot yet recruitingNCT06064344Not applicable
- A Pilot Bioequivalence Study of PomalidomideNot yet recruitingNCT06058689Phase 1
- Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell LymphomaRecruitingNCT06045247Phase 2
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06015880Phase 1
- Efficacy of Intravenous Immunoglobulin in Patients With Hemorrhagic Fever With Renal Syndrome: a Prospective StudyRecruitingNCT06009042Phase 4
- Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaRecruitingNCT06006117Phase 3
- Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RSNot yet recruitingNCT06004765Phase 4
- Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid ArthritisRecruitingNCT06003283Phase 4
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT05991388Phase 2/3
- The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.Not yet recruitingNCT05990985Not applicable
- A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's MacroglobulinemiaRecruitingNCT05979948Phase 2
- Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLRecruitingNCT05952024Phase 2
- Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05940051Phase 2
- Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System InvolvementRecruitingNCT05926427Phase 2
- Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple MyelomaRecruitingNCT05922501Phase 2
- Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMRecruitingNCT05914662Phase 2
- Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT05910801Phase 2
- A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple SclerosisRecruitingNCT05906992Phase 3
- Delayed Tolerance Through Mixed ChimerismRecruitingNCT05900401Phase 1/2
- Comparison of a Personalized Maintenance Therapy With the Standard Treatment in PemphigusRecruitingNCT05898308Phase 4
- Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCTRecruitingNCT05896007Phase 2
- Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)RecruitingNCT05868837Phase 3
- Immune Thrombocytopenia Management in AdultsRecruitingNCT05861297Phase 4
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaRecruitingNCT05861050Phase 1/2
- Rituximab in the First Episode of Paediatric Nephrotic SyndromeNot yet recruitingNCT05850546Phase 3
- Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapyRecruitingNCT05848765Phase 2
- Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone LymphomaRecruitingNCT05846750Phase 2
- Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic SyndromeRecruitingNCT05843968Phase 2
- Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MSRecruitingNCT05834855Phase 3
- Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCCNot yet recruitingNCT05831969Phase 2
- Anti-CD20 Antibodies for Treatment of SLE-PAHRecruitingNCT05828147Phase 4
- Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsRecruitingNCT05809180Not applicable
- Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingNCT05789303Phase 2
- Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative DisorderRecruitingNCT05786040Phase 2
- Epcoritamab and Rituximab for First-line Follicular LymphomaRecruitingNCT05783609Phase 2
- Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma PatientsRecruitingNCT05776979Phase 2
- A Clinical Study of Injectable IMM0306 in Combination With LenalidomideNot yet recruitingNCT05771883Phase 1/2
- A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic AnemiaRecruitingNCT05757310Phase 1
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)RecruitingNCT05736419Phase 2
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingNCT05735717Phase 2
- Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled TrialRecruitingNCT05734794Phase 3
- The Study of ICP-248 in Patients With Mature B-cell MalignanciesRecruitingNCT05728658Phase 1
- Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple MyelomaRecruitingNCT05722405Phase 4
- Selinexor in Combination With MTX+Ritu to Treat R/R CNSLRecruitingNCT05698147Phase 1/2
- GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5RecruitingNCT05695508Phase 2
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT05651932Phase 1
- Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaRecruitingNCT05645718Phase 2
- Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell LymphomaRecruitingNCT05635162Phase 2
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLRecruitingNCT05615636Phase 2
- Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)RecruitingNCT05604859Phase 4
- Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System LymphomaRecruitingNCT05600660Phase 2
- Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized TrialRecruitingNCT05596786Phase 3
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaRecruitingNCT05583617Phase 1/2
- Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSLRecruitingNCT05583071Phase 2
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide RefractoryNot yet recruitingNCT05581875Phase 1/2
- Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT05575973Phase 2
- A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple MyelomaRecruitingNCT05573802Phase 1/2
- Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCLRecruitingNCT05552937Phase 2
- Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in ChildrenRecruitingNCT05520892Phase 4
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingNCT05519085Phase 3
- Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell LymphomaRecruitingNCT05504603Phase 2
- Lenalidomide in the Treatment of Mucosal Behçet's SyndromeRecruitingNCT05449548Not applicable
- The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.RecruitingNCT05428670Phase 2
- Selinexor Plus VRd in High Risk Newly Diagnosed Multiple MyelomaRecruitingNCT05422027Phase 1/2
- Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)RecruitingNCT05418010Phase 2
- Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSLRecruitingNCT05390749Phase 2
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasRecruitingNCT05389423Phase 1
- Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple MyelomaRecruitingNCT05378971Not applicable
- Tafasitamab Plus Lenalidomide in Relapsed CNS LymphomaRecruitingNCT05351593Phase 1/2
- Genotype-guided Treatment in DLBCLRecruitingNCT05351346Phase 3
- Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2Enrolling by invitationNCT05350774Phase 2
- Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
- Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple MyelomaRecruitingNCT05344833Phase 2